Introduction
============

In developed countries, HIV guidelines recommend a nonnucleoside reverse transcriptase inhibitor (NNRTI), a boosted protease inhibitor (bPI) or an integrase inhibitor associated with a nucleos(t)ide reverse transcriptase inhibitor (N(t)RTI) backbone as first-line therapy for individuals with HIV-1 infection [@R1].

In resource-limited settings (RLS), the WHO recommends the use of two N(t)RTIs and one NNRTI as first-line antiretroviral therapy (ART). The new 2013 recommendations state that EFV should be the first choice as NNRTI and ART should be started when CD4^+^ cell count is below 500 cells/μl (<http://www.who.int/hiv/pub/guidelines/arv2013>). However, in countries where NVP remains the first choice, the later criteria will be an issue owing to its contraindication for women with CD4^+^ cell count above 250 cells/μl and men with more than 400 cells/μl.

In RLS, three key problems are of concern with the use of NNRTI-based ART. First, there is evidence for an increasing baseline resistance to N(t)RTIs and NNRTIs among treatment-naive patients, which may compromise the efficacy of these treatments [@R2], particularly in sub-Saharan Africa where the estimated prevalence of primary NNRTI resistance reached 3.4% in 2009 [@R3]. Second, due to limited or no monitoring for plasma HIV RNA during therapy, treatment failures remain undetected for months or years and drug resistance mutations (DRMs) accumulate precluding a successful switch to a second-line therapy, and third, patients developing NNRTI/NRTI drug resistance may transmit resistant virus to sexual partners [@R4]. Therefore, in RLS, the need to maximize the effectiveness of available first-line regimens and to sustain reduced morbidity and mortality remains a major challenge for ART programmes [@R2]. When compared with NNRTIs, bPI regimens are more forgiving when adherence is relatively low [@R6] and protect against emergence of resistance of NRTIs in long-term failing patients [@R7], even in settings with low or absent virologic monitoring [@R8]. NVP being the NNRTI of choice in Democratic Republic of Congo (DRC) in 2008, the Lubumbashi trial was designed to assess the efficacy and safety of initial ART with NVP compared with lopinavir/ritonavir (LPV/r) with two backbones recommended by WHO, either tenofovir disoproxyl fumarate/emtricitabine (TDF/FTC) or zidovudine/lamivudine (ZDV/3TC).

Materials and methods
=====================

Study design and individuals
----------------------------

Patients were randomized in an open-label, multicentre, parallel group superiority study conducted in Lubumbashi (DRC), the capital of the Katanga region, a city of one million inhabitants and an estimated HIV prevalence of 6% in adults in 2006. Eligible participants were adults, recruited through advertisements, who were ART-naive (previous single NVP dose for prevention of mother-to-child transmission was allowed) with an indication to start ART according to the Congolese National HIV treatment guidelines (WHO clinical stage 3 and CD4^+^ cell count \<350 cells/μl, or clinical stage 4 or a CD4^+^ cell count \<200 cells/μl regardless of WHO clinical stage). Main exclusion criteria were active tuberculosis, haemoglobin less than 8.5 g/dl in women and less than 9.0 g/dl in men, alanine aminotransferase or aspartate aminotransferase more than three times the upper limit of normal and creatinine clearance less than 50 ml/min.

Eligible individuals were randomized (1 : 1) with a simple randomization procedure based on computerized random numbers to receive: LPV/r (Aluvia; Abbott Laboratories) 800/200 mg/day \[taken daily (q.d.) or twice daily (b.i.d.) at the patient choice\] or NVP 200 mg b.i.d. combined with either TDF/FTC (300/200 mg) fixed-dose combination (FDC) (Truvada; Gilead Sciences Inc.) or ZDV/3TC, 300/150 mg generic fixed-dose combination. TDF/FTC replacing ZDV/3TC in individuals with positive hepatitis B surface antigen. These two backbones are recommended by the WHO and are available through the National Programme in DRC. Therefore, the allocated backbone was also randomly chosen with no *a priori* hypothesis about their respective therapeutic effect. Patients treated with NVP started with a 2-week lead-in period at 200 mg daily. Nevirapine was chosen because in 2008 it was the first choice in association with ZDV and 3TC in the national guidelines in DRC. Following the new recommendations of the WHO, EFV is now the preferred NNRTI. Trimethoprim/sulfamethoxazole (80/400 mg) daily prophylaxis was systematically given. Patients failing on NVP or LPV/r were allowed to switch to the other arm on the basis of the genotypic analysis. In case of treatment-limiting toxicity to the randomized dual N(t)RTI or to NVP or LPV/r, a switch to the alternate drug(s) was allowed.

Patients who developed active tuberculosis were discontinued from the study and switched to an efavirenz and rifampin-based treatment.

Study oversight
---------------

The study was approved by the National Ethical Committee in DRC and by the Ethical Committees of Saint-Pierre University Hospital, Brussels and the University of Liège in Belgium. Written informed consent was obtained from all participants. An independent data and safety monitoring committee blindly reviewed the efficacy and safety data after all patients have completed 24 weeks in the study. LPV/r and TDF/FTC, respectively, were donated by Abbott and Gilead Laboratories who played no role in the final design decisions of the study, the analysis of data or preparation of the manuscript. All others drugs were available through the National AIDS Program in DRC.

Study assessments
-----------------

Clinical assessments were performed at screening, baseline, week 2, 4, 12 and every 12 weeks thereafter for 96 weeks. The treating physician assessed patient\'s adherence at each visit on the basis of pill counts and patients self-administered questionnaires. Counselling and support were given in case of adherence difficulties and detectable HIV-1 viral load.

Laboratory safety assessments were performed every 12 weeks. Hepatitis B and C serologies were assessed at baseline.

CD4^+^ cell counts and plasma HIV-1 RNA (Amplicor HIV-1 Monitor assay, 1.5; F. Hoffman-La Roche Ltd) were done at baseline, week 12 and every 24 weeks thereafter by a central local university laboratory. Virologic failure was defined as two consecutive (taken 15--30 days apart) plasma HIV-1 viral load at least 1000 copies/ml after week 24 after starting therapy. We used a threshold of 1000 copies/ml because it is commonly used in most routine laboratory for genotypic determination. Since 2013, this limit is considered by WHO as an early site-based warning indicator of treatment failure in developing countries (<http://www.who.int/hiv/pub/guidelines/arv2013>), with the goal of ART remaining to achieve and sustain viral suppression. For all individuals with confirmed virologic failure, genotype sequencing was performed centrally on baseline sample and on sample taken at the time of VF, using the TRUGENE HIV-1 genotyping kit (Global Siemens Healthcare) and OpenGene DNA sequencing system. DRMs and HIV clades were interpreted using the HIVdb Program, 2011, from Stanford ([http://hivdb.stanford.edu](http://hivdb.stanford.edu/)). For minority variant determination, DNA sequencing clonal analysis of the reverse transcriptase and protease amplified products sequencing at least 200 clones per sample was performed. Antiretroviral plasma levels were determined by liquid chromatography coupled with tandem mass spectrometry in samples collected at the time of virologic failure.

Study endpoints
---------------

The primary objective of the study was to assess whether lopinavir/ritonavir is superior to nevirapine at week 48 when both are combined with one of the WHO-recommended NRTI backbones (TFD/FTC or ZDV/3TC). Follow-up was made until week 96. The primary endpoint was the number of patients who have reached a therapeutic failure endpoint, a composite of clinical or virologic failure.

Clinical failure was defined as the occurrence of a WHO stage 4 or WHO stage 3 event or death after at least 24 weeks of therapy, or a discontinuation of study drugs for toxicity at any time. Virologic failure was defined as confirmed plasma HIV-1 viral load of at least 1000 copies/ml after week 24 after starting therapy.

Secondary endpoints included the proportion of patients with plasma HIV-1 RNA viral load below 50 copies/ml, CD4^+^ cell counts changes from baseline, HIV-1 resistance mutations, adherence and safety of the four regimens. The proportion of patients with a viral load below a threshold of 400 copies/ml was also assessed (exploratory analysis). A separate analysis between patients with baseline viral load above 100 000 copies/ml was also performed (exploratory analysis).

Statistical analyses
--------------------

Assuming a rate of 15% of patients with clinical or virological failure in the LPV/r arm and 30% in the NVP arm at week 48, a sample size of at least 174 evaluable patients by arm was considered necessary to detect a difference of 15% with a 90% power and a significant alpha level of 0.05 using a Fisher\'s exact two-sided test. Assuming a rate of 25% of loss to follow-up, a proportional oversampling was made.

The rate of therapeutic failure defined as a composite of clinical and virological endpoint in randomized treatment groups was compared for superiority using a modified intention-to-treat (mITT) analysis, which included data for all patients who were assigned to a treatment group and who have taken at least one dose of study medication regardless of any reason of discontinuation. In this analysis, patients who died before week 24 had tuberculosis before week 24, withdrew their consent, had a protocol violation or were lost to follow-up were counted as failure. Missing HIV-1 RNA viral load data were imputed as failure irrespective of the reason of absence.

We also did a per-protocol analysis on all the individuals who received study drugs up to 48 and 96 weeks and who did not discontinue the study treatment for another reason than therapeutic failure as defined above.

The differences between treatment groups (nevirapine-lopinavir/ritonavir) are presented in terms of risk difference and associated two-sided 95% confidence intervals. We used the Cochran--Mantel--Haenszel test to assess virologic and overall therapeutic responses adjusted according to the backbones of the patients. All other *P*-values are unadjusted.

Simple descriptive statistics were used for summarizing characteristics of patients by arm at baseline using median and interquartile ranges (IQRs) for continuous data, and frequencies and percentages for categorical data.

Other analyses of efficacy or safety between groups of patients were performed at considered week with the Mann--Whitney *U* test if the data were continuous and Fisher\'s exact test if the data were categorical.

Clinical and laboratory-associated adverse events occurring when the patients were still on the treatment assigned at the randomization were included in the safety analyses. Adverse events were recorded as drug-related if they were judged by the investigator to be definitely, probably or possibly related to any of the study drugs. Intensity grading was based on the Division of AIDS (DAIDS) toxicity guidelines for adults (2004).

The comparison between the backbones was only exploratory and focused on the safety data.

A posthoc analysis was performed to assess the sexual difference outcomes between treatment groups. Breslow--Day test for homogeneity of odds ratio was used to verify the existence of an interaction between sex, treatment groups and endpoints. All reported *P*-values are two-sided.

Analysis and graphs were produced using SAS statistical software (version 9.2; SAS Institute, Cary, North Carolina, USA).

Results
=======

Patients disposition and baseline characteristics
-------------------------------------------------

We screened 724 individuals between December 2008 and October 2009 of whom 299 (41.2%) were not eligible. Four hundred and twenty-five (58.7%) patients were randomized \[209 (49.1%) in NVP and 216 (50.8%) in LPV/r groups\] and took at least one dose of study drugs. The number of individuals who have discontinued the study before week 96 was similar in both groups ([Fig. 1](#F1){ref-type="fig"}). At week 96, 28 (6.6%) patients were lost to follow-up and 25 (5.9%) had a major protocol violation (20/25 individuals were found to be not treatment-naive at the inclusion).

![Individual\'s disposition.](aids-28-1143-g001){#F1}

Demographics and baseline characteristics were well balanced across both treatment groups ([Table 1](#T1){ref-type="table"}). Median CD4^+^ cell count (cells/μl) was 181 (IQR: 77--256) and 165 (IQR: 92--250) in men and women, respectively. In the NVP group, 24% of women (35/148) had CD4^+^ cell count more than 250 cells/μl. Thirty-four out of 216 (15.7%) patients started with LPV/r once daily.

Primary endpoints
-----------------

In the mITT analysis that considers all patients who received at least one dose of study medication together with the other reasons of discontinuation, there was no difference in the rate of therapeutic failure between NVP and LPV/r-based regimens: at week 48, 32% (67/209) in NVP compared with 29% (63/216) in LPV/r (*P* = 0.53); and at week 96, 42% (88/209) in NVP compared with 38% (83/216) in LPV/r (*P* = 0.49) ([Table 2](#T2){ref-type="table"}a). For the overall group, death occurred in 42 out of 425 (9.9%) patients mostly before week 24 (30/42, 71%) with no difference between treatment groups. Causes of deaths are reported in supplemental page Table 1.

In the per-protocol analysis at week 48, the rate of therapeutic failure in the nevirapine arm was twice the one in the ritonavir-boosted lopinavir arm: 15% (25/167) in NVP compared with 8% (13/166) in LPV/r (*P* = 0.04) ([Table 2](#T2){ref-type="table"}b). This difference was mostly due to a higher rate of virologic failure among the individuals treated with nevirapine (19/167; 11.4%) versus those receiving LPV/r (7/166; 4.2%) (*P* = 0.015). At week 96, the higher proportion of patients with virologic failure in the NVP arms persisted: 27/158 (17.1%) as compared with 13/159 (8.2%) in LPV/r groups (*P* = 0.018). This difference remained statistically significant (*P* = 0.04) when the three patients with a baseline resistance to NVP were excluded from the analysis. mITT analysis among the individuals with baseline viral load more than 100 000 copies/ml did not find any difference in treatment outcomes at week 48 (*P* = 0.54) and week 96 (*P* = 0.15).

The analysis carried out on all patients who took at least one dose of study drugs and adjusted to backbone showed no differences in therapeutic failure endpoints at week 48 (adjusted *P* = 0.538; Cochran--Mantel--Haenszel test) and at week 96 (adjusted *P* = 0.456).

Secondary endpoints
-------------------

Secondary endpoints have been assessed in all patients who received at least one dose of study medication. The median change from baseline in CD4^+^ cell count at week 48 was 119 cells/μl (range: 49--198) for NVP vs. 125 cells/μl (range: 66--199) for LPV/r (*P* = 0.473), and at week 96 was 161 cells/μl (range: 66--255) for NVP vs. 181 cells/μl (range: 69--312) for LPV/r (*P* = 0.181).

No difference was observed between the treatment groups in the proportion of patients with HIV-1 RNA less than 50 copies/ml at week 48: 68% (NVP) vs. 67% (LPV/r) (*P* = 0.699) and at week 96: NVP (63%) vs. LPV/r (60%) (*P* = 0.597) (supplemental figure). When considering a cut-off of 400 copies/ml, the proportion of individuals above this threshold was still significantly higher in the nevirapine than in lopinavir/ritonavir-based treatments at week 48 \[10% (21/209) vs. 4% (9/216), *P* = 0.012\] but not at week 96 \[14% (29/209) vs. 8% (17/216), *P* = 0.060\].

Resistance data
---------------

At baseline, major DRMs were found in three out of 27 (two women, one man) NVP-failing patients and in zero out of 13 patients who failed in the LPV/r group. In addition, no minority variants with resistance mutations were found in any patients who developed virologic failure during the trial.

At the time of failure, DRMs to NNRTI, N(t)RTIs or both classes were detected among 19 out of 22 (86.3%), 15 out of 22 (68.2%) and 15 out of 22 (68.2%) of patients receiving NVP, respectively ([Table 3](#T3){ref-type="table"}). Pattern of mutations selected in the NVP group (Y181C/V, K101E) showed a predicted decreased susceptibility to etravirine or rilpivirine in 50% of individuals. In the subgroup of patients on NVP-TDF/FTC, K65R was found in seven out of 14 patients (three clade C, two clade G, one clade A, one clade K). In the bPI group, no major protease inhibitor mutations emerged and NRTI-DRM (M184V/I) occurred in two out of 10 patients.

Adherence
---------

The proportion of patients with adherence at least 95% at each study visit was similar between the treatment groups up to 48 weeks; 75.4 vs. 74.6% (*P* = 0.906) and up to 96 weeks; 75.9 vs. 75.5% (*P* = 1) for NVP and LPV/r, respectively.

The proportion of individuals with an adherence of at least 95% was lower in patients with a virologic failure than in those without virologic failure (60 vs. 77.4%; *P* = 0.019) up to 96 weeks. Measures of plasma drug concentrations confirmed the poor adherence in failing patients; NVP plasma concentrations were inadequate (\<3000 ng/ml) in 14 out of 22 (63.6%) patients and LPV plasma level was below the limit of quantification in 10 out of 10 failing patients.

Safety
------

Most adverse events were observed during the first 48 weeks. There were more patients with adverse events in the LPV/r arm (59/216; 27.3%) than in the NVP arm (34/209; 16.2%) (at week 48 *P* ≤ 0.0069) ([Table 4](#T4){ref-type="table"}a). Gastrointestinal side effects were more frequent in the LPV/r groups, whereas rashes were significantly higher among patients on NVP. Two patients on LPV/r and two patients on NVP changed their therapy for grade 3 toxicity.

The preplanned exploratory analysis focused on the backbone safety comparison is shown on [Table 4](#T4){ref-type="table"}b. Zidovudine/lamivudine was discontinued in seven (3.5%) individuals (all for anaemia) compared with tenofovir/emtricitabine in only one (0.4%) individual (for renal failure), *P* = 0.029.

Nausea, vomiting and neutropenia were more frequently reported with ZDV/3TC than with TDF/FTC.

No difference was seen between backbones in median estimated glomerular filtration rate (eGFR) changes from baseline (which remained within the normal range).

Posthoc sexual analysis
-----------------------

At week 48, sexual analysis did not show any difference in outcomes.

At week 96, men, as compared with women had a lower median CD4^+^ cell count increase \[105 cells/μl (IQR: 34--188) vs. 197 cells/μl (IQR: 84--319) *P* \< 0.0001\] and developed more tuberculosis (6/120; 5% vs. 4/305; 1.3%; *P* = 0.034).

Discussion
==========

In this prospective trial comparing a NNRTI-based first-line ART with a bPI regimen, mITT analysis demonstrated equivalent outcomes of both strategies. Per-protocol analysis demonstrated more virologic failures and DRMs among patients who received a NNRTI-based regimen than those who received a bPI-based regimen. Although discontinuation for severe adverse events was similar in both groups, NVP-based regimen was better tolerated than LPV/r regimen. No difference in outcomes was seen in relation with the NRTI backbones.

Few randomized trials have been conducted in RLS to compare NNRTI vs. bPI-based regimen as first-line ART in adults [@R9]. Among 500 African women who had no prior exposure to single-dose NVP, initial NVP-TDF/FTC was as effective as LPV/r-TDF/FTC in terms of virologic failure and death [@R9]. In a South African trial, no differences in virological outcome were found between LPV/r and EFV treatment arms [@R10]. The apparent discrepancy in rate of virologic failure between the above-mentioned trials and our trial may be related to a different definition of virologic failure [@R11]. Virologic failure rates are highly sensitive to thresholds and the choice of HIV RNA cut-off to define viral failure may lead to an underestimation of the prevalence of resistance [@R12]. In the above-mentioned studies, a cut-off of 400 copies/ml was used to define virologic failure. With a threshold of 1000 copies/ml, our failure rate of 12.9% among patients treated with NVP-based regimens for 24 months is consistent with the results of observational studies. In 2008, in the Democratic Republic of Congo, 14.6% of patients had a plasma viral load more than 1000 copies/ml after a median time on NNRTI regimen of 25 months [@R13]. In the systematic review by Barth *et al.*[@R14] of 89 studies with 13 288 patients with a median duration of treatment of 10 months, the prevalence of virologic failure after 24 months was 33%.

In our study, virologic failure was not driven by pretreatment transmitted drug resistance. Indeed, only three out of 27 individuals who failed on NVP had NNRTI resistance at baseline. We found no minority resistance mutation at baseline in the remaining individuals. Our pharmacokinetic data and adherence measures are consistent with previous observations that suboptimal adherence is associated with an increased risk of emergence of DRMs in case of NNRTI-based therapy in contrast with bPI-based therapy [@R6].

No protease inhibitor mutations and only minimal NRTI resistance being found among LPV/r failing patients, our study also confirms that bPI-based regimens have a more 'forgiving' profile in terms of emergence of resistance [@R6]. Of those patients with virologic failure, 86% had drug-resistant mutation to NNRTI and 50% were predicted to harbour HIV strains with reduced susceptibility or drug resistance to etravirine or rilpivirine, a relevant finding if these drugs would be considered for future salvage therapy in RLS [@R18]. High frequency of NRTI mutations and dual resistance to NNRTI-NRTI were also found that limit the choice and response to a second-line therapy. Mutations associated with cross-resistance to NRTIs comprised multiple thymidine-associated mutations (18%) or K65R (32%). This high level of K65R in patients failing on TDF confirms the association with subtype C clades as compared with subtypes B and is consistent with a meta-analysis showing that genotypic resistance to NRTIs appears far greater in RLS [@R19].

Because our participants were evaluated for viral load every 6 months after week 24, it is not surprising that observed resistant patterns were more extensive for this trial than for cohorts that received intensive virologic monitoring [@R16]. In the absence of viral load monitoring, similar high frequencies of DRM (70--93%) were reported in persons with prolonged ART failure [@R22]. In most sub-Saharan countries, the diagnosis of therapeutic failure is still based on clinical and immunological criteria that are not sensitive or specific enough leading to late or inappropriate switch to second-line regimen [@R27]. A recent editorial has stressed the public health priority in RLS to implement viral load testing as a standard monitoring tool [@R28].

Although this study was not designed to evaluate differences between men and women, our results suggest also that men had a poorer clinical and immunological outcome in response to ART. In RLS, poorer outcomes have been constantly observed in men, including a higher risk of opportunistic infections, mortality and virologic failure [@R29]. So far, late access to care, differences in behaviour and lower adherence to therapy have been advocated to explain these sexual differences [@R31].

Our study has some limitations; we used NVP as NNRTI-based regimen. One cannot exclude that with an EFV-based regimen, rates of virologic failure would be lower [@R32]. However, in case of virologic failure, NNRTI resistance mutations have been shown to remain significantly higher with EFV than with bPI and our conclusions on the robustness of bPI regimen would not change [@R10].

This study was not designed to see differences in outcomes between backbone and no definitive conclusions could be driven from our results.

This trial was conducted at clinics in a large city and does not reflect the routine of care in smaller cities and rural healthcare facilities. Public health decisions cannot be solely based on randomized clinical trials in settings with fewer constraints and optimal follow-up.

Although resistance considerations need to be balanced against other factors, such as cost, coformulation as fixed-dose combinations, short and longer-term toxicity, administration of ART with tuberculosis medication and lack of second-line availability following protease inhibitor use as a first-line regimen, it remains that particularly in sub-Saharan Africa, important gaps in service delivery and programme performance affecting a considerable proportion of ART programmes contribute to substandard antiretroviral regimen and acquired drug resistance [@R34]. This worrying situation reinforces the need, among other public health interventions, to maximize the effectiveness of available first-line regimen taking into account unplanned treatment interruptions and patients with a risk of poor adherence particularly in the absence of baseline genotypic determination and viral load monitoring. This is even more important since the implementation of the 2013 WHO guidelines, which will substantially increase the number of patients on ART and in the current settings of suboptimal therapies and lack of viral load monitoring may critically increase the level of resistance development. In such a setting, bPI-containing regimen might be a better suited first-line ART option in RLS that might improve rates of viral suppression and reduce treatment-emergent drug resistance. In case of virologic failure with bPI, due to the absence of major protease inhibitor mutations and infrequent minority variant resistant mutations [@R35], bPI could possibly be reused with a different antiretroviral backbone including integrase inhibitors [@R36]. In the next years, availability of other classes for second-line regimens, decreased prices and development of new drug formulation, following WHO prequalification and FDA approval of atazanavir/ritonavir FDC in late 2011, should facilitate strategic decisions regarding future switch of first-line combination ART to bPI.
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###### Supplemental Digital Content

###### 

Baseline characteristics.

  Randomized patients                                     NVP *n* = 209       LPV/r *n* = 216
  ------------------------------------------------------- ------------------- -------------------
  Age (years), median (IQR)                               38 (33--45)         38 (33--45)
  Female                                                  148 (70.8%)         157 (72.7%)
  Previous exposure to NVP single dose for PMTCT          2                   1
  Black race                                              209 (100%)          216 (100%)
  Weight (kg), median (IQR)                               55 (50--62)         54 (49--62)
  BMI (kg/m^2^), median (IQR)                             21 (19--23)         20 (18--23)
  WHO stage                                                                   
   CD4^+^ cell count \<200 cells/μl                       121 (58%)           128 (59%)
   Stage III, *n* (%)                                     190 (90.9%)         202 (93.5%)
   Stage IV, *n* (%)                                      10 (4.8%)           5 (2.3%)
  CD4^+^ cell count (cells/μl) -- median (IQR)            164 (84--253)       168 (84--253)
  CD4^+^ cell count \<100 cells/μl                        60 (28.7%)          61 (28.2%)
  Plasma HIV RNA (log copies/ml), median (IQR)            5.17 (4.5--5.6)     5.13 (4.4--5.6)
  Plasma HIV RNA \>100 000 copies/ml (%)                  115 (55%)           115 (53%)
  Clades (*n*)                                                                
   Clade C (%)                                            60.6                60.0
   Clade A (%)                                            10.6                11.2
   Clade G (%)                                            7.3                 7.2
   Clade K (%)                                            8.1                 6.4
   Other (%) (B, D, F, H, J, CRF01, CRF01_AE, CRF02_AG)   13.4                15.2
  Hep B surface antigen, positive, *n* (%)                18 (8.6%)           22 (10.2%)
  Hep C antibody, positive, *n* (%)                       7 (3.3%)            8 (3.7%)
  Hb, mmol/l, median (IQR)                                6.8 (6.2--7.4)      6.8 (6.2--7.4)
  eGFR (Cockcroft--Gault; ml/s), median (IQR)             1.17 (1.00--1.34)   1.12 (0.97--1.30)

IQR, interquartile range; PMTCT, prevention of mother-to-child transmission.

###### 

Treatment outcome at week 48 and week 96.

  \(a\) Comparison between NVP vs. LPV/r-based regimens; mITT analysis           Week 48         Week 96                                                                                                          
  ------------------------------------------------------------------------------ --------------- ----------------- -------------------------- ------ --------------- ----------------- -------------------------- ------
  Primary endpoints, *n* (%)                                                                                                                                                                                      
  Clinical failure                                                                                                                                                                                                
   New or recurrent WHO clinical stage III or IV event                           4 (1.9)         2 (0.9)           −1% (−3 to 1)                     7 (3.3)         8 (3.7)           0.4% (−3 to 3)             
   Death after 24 weeks                                                          0 (0)           2 (0.9)           1% (−0.4 to 2)                    1 (0.4)         3 (1.4)           1% (−1 to 3)               
   Changing of treatment for toxicity                                            2 (1)           2 (0.9)           −0.3% (−2 to 2)                   2 (1)           2 (0.9)           −0.1% (−2 to 2)            
  Virologic failure (plasma VL \>1000 copies/ml)                                 19 (9.1)        7 (3.2)           −5.9% (−10 to −1)                 27 (12.9)       13 (6)            −6.9% (−12.4 to −1.4)      
  Other reasons off treatment, *n* (%)[^a^](#TF2-1){ref-type="table-fn"}         42 (20.1)       50 (23.1)         3% (−5 to 11)              0.48   51 (24.4)       57 (26.4)         2% (−6 to 10)              
  Total outcomes, *n* (%)                                                        67 (32.1)       63 (29.2)         −2.9% (−11.7 to 5.9)       0.52   88 (42.1)       83 (38.4)         −3.7% (−13 to 5.6)         0.48
  \(b\) Comparison between NVP vs. LPV/r-based regimens; per-protocol analysis   Week 48         Week 96                                                                                                          
                                                                                 NVP *n* = 167   LPV/r *n* = 166   Risk difference (95% CI)   *P*    NVP *n* = 158   LPV/r *n* = 159   Risk difference (95% CI)   *P*
  Primary endpoints, *n* (%)                                                                                                                                                                                      
  Clinical failure                                                                                                                                                                                                
   New or recurrent WHO clinical stage III or IV event                           4 (2)           2 (1.2)           −1.2% (−4 to 1.7)                 7 (4)           8 (5)             0.6% (−4.1 to 5.3)         
   Death after 24 weeks                                                          0 (0)           2 (1.2)           1.2% (−0.4 to 2.9)                1 (1)           3 (2)             1.3% (−1.2 to 3.7)         
  Changing of treatment for toxicity                                             2 (1.2)         2 (1.2)           0% (2.3 to −2.3)                  2 (1)           2 (1)             0% (1.3 to −1.3)           
  Virologic failure (plasma VL \>1000 copies/ml)                                 19 (11)         7 (4.2)           −7% (−13 to −1)            0.01   27 (17)         13 (8)            −9% (−16 to −2)            0.02
  Total outcomes, *n (%)*                                                        25 (15)         13 (7.8)          −7.1% (−13.9 to −0.4)      0.04   37 (23%)        26 (16%)          −7% (−16 to 2)             0.11

^a^Death before week 24, tuberculosis before week 24, consent withdrawal, protocol violation, lost to follow-up, missing data.

###### 

Virologic results and drug resistance mutations (at week 96).

                                                                                        NVP *n* = 209                         LPV/r *n* = 216   *P*
  ------------------------------------------------------------------------------------- ------------------------------------- ----------------- ----------
  Number of patients with VF, *n* (%)                                                   27 (13)                               13 (6)            0.019
   Genotype available at VF, *n* (%)                                                    22 (82)                               10 (77)           
   Any resistance-associated mutation at baseline, *n*                                  3[^a^](#TF3-1){ref-type="table-fn"}   0                 
   Resistance-associated mutations at VF (excluding minor protease mutation), *n* (%)   19 (86)                               2 (20)            \<0.0001
   NNRTI-associated mutation, *n* (%)                                                   19 (86)                               0                 \<0.0001
    K103N                                                                               13 (59)                               0                 
    Y181C/V                                                                             10 (45)                               0                 
    Other[^b^](#TF3-2){ref-type="table-fn"}                                             12 (54)                               0                 
   N(t)RTI-associated mutation, *n* (%)                                                 15 (68)                               2 (20)            0.020
    M184V/I                                                                             15 (68)                               2 (20)            0.020
    K65R                                                                                7 (32)                                0                 0.069
    Thymidine analogue associated mutation[^c^](#TF3-3){ref-type="table-fn"}            4 (18)                                0                 
   N(t)RTI along with NNRTI associated mutation, *n* (%)                                15 (68)                               0                 \<0.0001
   Any protease mutation, *n* (%)                                                       0                                     1 (10)            
   Major protease mutation, *n*                                                         0                                     0                 

Resistance-associated mutations according to IAS-USA, 2011 list. N(t)RTI, nucleoside or nucleotide reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; VF, virologic failure.

^a^NNRTI mutations: K103N, Y181C, V108I; N(t)RTI mutations: M184V, L210W.

^b^Other NNRTI mutations: K101E, V106I/L, V108I/L, Y188C, G190A, F227L, M230L, P236H.

^c^Thymidine analogue-associated mutation: 41L, 67N, 70R, 210W, 215F/Y, 219Q/E.

###### 

Safety analysis through 96 weeks.

  \(a\) Comparison between NVP vs. LPV/r-based regimens                     Week 0 to week 48   Week 48 to week 96                                                      
  ------------------------------------------------------------------------- ------------------- -------------------- ---------- ------------------- ------------------- -------
  Patients with at least one clinical adverse event, *n* (%)                34 (16.2)           59 (27.3)            0.007      0                   3 (1.4)             0.249
  Adverse events leading to study drug discontinuation, *n* (%)             2 (0.9)             2 (0.9)              1          0                   0                   
  Clinical events (grade 1--4)[^a^](#TF4-1){ref-type="table-fn"}, *n* (%)                                                                                               
   Rash                                                                     8 (3.8)             0                    0.003      0                   0                   
   Vomiting                                                                 15 (7.2)            29 (13.4)            0.038      0                   2 (0.9)             0.499
   Diarrhoea                                                                0 (0)               32 (14.8)            \<0.0001   0                   3 (1.4)             0.249
   Nausea                                                                   20 (9.6)            40 (18.5)            0.008      0                   0                   
  Laboratory abnormalities (grade 3--4)[^a^](#TF4-1){ref-type="table-fn"}                                                                                               
   Hepatic aminotranferase (\>5.1× ULN)                                     5 (2.4)             3 (1.4)              0.497      2 (0.9)             1 (0.46)            0.618
   Haemoglobin (\<4.65 mmol/l)                                              17 (7.9)            17 (8.1)             0.863      2 (0.9)             1 (0.46)            0.618
   eGFR (\<0.835 ml/s)                                                      3 (1.4)             2 (0.9)              0.681      0                   0                   
  \(b\) Backbones comparison                                                Week 0 to week 48   Week 48 to week 96                                                      
                                                                            TDF/FTC *n* = 225   ZDV/3TC *n* = 200    *P*        TDF/FTC *n* = 225   ZDV/3TC *n* = 200   *P*
  Patients with at least one clinical adverse event, *n* (%)                34 (15.1)           56 (28)              0.001      5 (2.2)             0                   0.063
  Adverse events leading to study drug discontinuation, *n* (%)             1 (0.4)             7 (3.5)              0.029      0                   0                   
  Clinical events (grade 1--4)[^a^](#TF4-1){ref-type="table-fn"}, *n* (%)                                                                                               
   Rash                                                                     6 (2.7)             2 (1.0)              0.291      0                   0                   
   Vomitting                                                                15 (6.7)            28 (14.0)            0.015      2 (0.88)            0                   0.501
   Diarrhoea                                                                17 (7.6)            15 (7.5)             1          3 (1.3)             0                   0.147
   Nausea                                                                   17 (7.6)            42 (21.0)            \<0.0001   0                   0                   
  Laboratory abnormalities (grade 3--4)[^a^](#TF4-1){ref-type="table-fn"}                                                                                               
   Hepatic aminotranferase (\>5.1× ULN)                                     6 (2.7)             1 (0.5)              0.126      2 (0.88)            0                   0.501
   Haemoglobin (\<4.65 mmol/l)                                              12 (5.3)            18 (9.0)             0.183      2 (0.88)            1 (0.05)            1
   Neutropenia (\<0.750 × 10^9^/l)                                          1 (0.4)             12 (6.0)             0.0014     0                   1 (0.05)            0.471
   eGFR (\<0.835 ml/s)                                                      1 (0.4)             2 (1.0)              0.603      0                   1 (0.05)            0.471
   Median change in eGFR from baseline (ml/s)                               +0.08               +0.13                0.201      +0.27               +0.24               0.832

eGFR, estimated glomerular filtration rate; ULN, upper limit of normal.

^a^Grading according with Division of AIDS Table for grading the severity of adult and paediatric adverse events, December 2004.
